drugset

drugset / Trial / NCT02014129

A Study of LY2835219 in Japanese Participants With Advanced Cancer

NCT02014129 ↗

Phase 1 Completed 12 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer.

Timeline

Start: 2013-12-18
Primary completion: 2015-04-01
Completion: 2019-08-21

Publications

Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abemaciclib	Small molecule	100 mg	Oral
Subject	Abemaciclib	Small molecule	150 mg	Oral
Subject	Abemaciclib	Small molecule	200 mg	Oral

Indications